Lifecore's Hapset plaster cleared for further use:
This article was originally published in Clinica
Lifecore Biomedical's hydroxylapatite bone graft plaster, Hapset, has been cleared for use in defect restorations in maxillary, mandibular and zygomatic sites. Hapset is currently cleared by the US FDA for use only in the restoration of periodontal and extraction socket bone defects in dental surgery. The company based in Chaska, Minnesota, estimates that approximately 430,000 maxillofacial bone repair procedures are performed annually in the US.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.